Eris Lifesciences Launches Affordable Generic Semaglutide 'Sundae' in India

Eris Lifesciences launched generic Semaglutide under the brand name 'Sundae,' following the expiry of its patent in India. The medication, crucial for diabetes and weight management, is priced affordably to boost accessibility. Natco Pharma also plans to launch its versions, Semanat and Semafull, in multi-dose vial formats.

In a major development for diabetes care, Eris Lifesciences on Friday introduced generic Semaglutide under the brand name 'Sundae' in India, as the molecule recently went off patent. This move is poised to make the medication for diabetes and weight management significantly more affordable, priced from Rs 1,290 per month.

The drug, available in multi-dose vials of 2 mg/1.5 ml and 4 mg/3 ml, is set to make a strong impact by providing cost-effective GLP-1 therapy to nearly 70 percent of diabetes patients in the country, according to Eris Lifesciences.

As domestic firms rapidly introduce their versions, Natco Pharma announced it will launch its Generic Semaglutide, with plans for multi-dose vials and a pen-device scheduled for the coming months, further enhancing patient accessibility and convenience.

(With inputs from agencies.)